Serum testosterone level, testosterone replacement treatment, and prostate cancer

16Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

There has been an increase in the number of individuals seeking testosterone (T) replacement treatment (TRT) due to a decrease in their blood T levels. Prostate cancer (PCa) is also an important issue in the same age group. However, we, urologists, are anxious about PCa development after T treatment. This is because it has been assumed that T may cause PCa or exacerbate insidious PCa which is already present. In this paper, recent developments regarding the relationship between serum levels of sex hormone and prostate tissue, the causal relationship between T and development of PCa, the effect of TRT on the group of patients who are at high risk of developing PCa, the suitability of TRT for patients who have already been diagnosed with PCa, and the effect of TRT on serum prostate-specific antigen level are analyzed. © 2013 Ali Atan et al.

Cite

CITATION STYLE

APA

Atan, A., Tuncel, A., Yesil, S., & Balbay, D. (2013). Serum testosterone level, testosterone replacement treatment, and prostate cancer. Advances in Urology. https://doi.org/10.1155/2013/275945

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free